The Hippo kinases MST1/2 and LATS1/2 inhibit the oncoproteins TAZ/YAP and regulate T cell function.
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Introduction
The evolutionary conserved Hippo pathway is a central regulator of tissue growth and cell fate. 1 In recent years, a wave of studies in animal models has demonstrated that its perturbation triggers tumorigenesis. 2 The core of the pathway (regulatory module) comprises the serine/threonine kinases mammalian STE20-like protein kinase 1 and 2 (MST1/2) and large tumor suppressor homolog 1 and 2 (LATS1). Hippo kinases, together with the adaptor proteins Salvador homologue 1 (SAV1) and MOB kinase activator 1A and 1B (MOB1A and MOB1B), mediate an inhibitory phosphorylation of two homologous oncoproteins: the transcriptional co-activator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP). 1,2 When TAZ/YAP are phosphorylated by Hippo kinases, they are retained in the cytoplasm, excluded from the nucleus, and undergo β-TRCP (β-transducin repeat-containing E3 ubiquitin protein ligase)-dependent degradation by the proteasome machinery. 1,2 Thus, it is generally accepted that the regulatory module exerts tumor-suppressive activities by negatively regulating the oncogenic Hippo transducers TAZ/YAP.
Overwhelming preclinical evidence linked Hippo pathway deregulation to breast cancer (BC). 3, 4 Among the plethora of tumor-promoting functions elicited by alterations in the Hippo signaling, particularly remarkable are those at the breast cancer stem cell (BCSC) level. [5] [6] [7] [8] [9] Indeed, studies investigating the biological consequences of aberrant Hippo activity in BCSCs configured a scenario where activation of TAZ/YAPdriven gene transcription promotes self-renewal, epithelial-mesenchymal transition (EMT), therapeutic resistance and distant dissemination. [5] [6] [7] [8] [9] Consistently, proof-of-concept, retrospective studies carried out by our group suggested that the expression of TAZ/YAP is associated with adverse therapeutic and survival outcomes in BC patients. [10] [11] [12] Nevertheless, the connection between the Hippo cascade and cancer extends beyond the canonical functions of the pathway. For instance, Hippo is involved in the biology of nonmalignant cells residing in the tumor microenvironment. In the context of the immune system, a noncanonical, Hippo/MST pathway is emerging as a central orchestrator of T cells activities, being implicated in an array of functions spanning from T cells development and activation to survival and trafficking. 13 Another level of regulation of core Hippo kinases refers to their cooperation with central nodes of the DNA damage response (DDR) machinery, chiefly the ataxia telangiectasia and Rad3-related protein (ATR)-Checkpoint kinase 1 (Chk1) and ataxia telangiectasia mutated (ATM)-Checkpoint Kinase 2 (Chk2) signaling avenues.
14
The ATR-chk1 and ATM-Chk2 pathways are deputed to initiate DNA repair upon genotoxic injuries, and their over-activation confers chemoresistant features. 15 Mechanistic studies unveiled that the Hippo-DDR cooperation promotes replication fork stability, cell-cycle checkpoint activation and DNA repair.
14 On this premise, we hypothesized that the expression of phosphorylated MST1/2 (pMST1/2) and LATS1/2 (pLATS1/2) may be associated with the efficacy of neoadjuvant therapy (NAT) in BC patients in a contextdependent manner. In greater detail, we envisioned the following "Janus-faced" role for Written informed consents were obtained before chemotherapy.
Immunohistochemistry
The immunohistochemical assessment of pMST1/2 and pLATS1/2 was performed in formalin-fixed paraffinembedded (FFPE) tissues, related to diagnostic biopsies, using the following antibodies: anti-MST1/2 (phospho T183) rabbit polyclonal antibody (Abcam) at the dilution of 1:50 (pH 8); and anti-LATS1/2
(phospho T1079 and T1041) rabbit polyclonal antibody (Abcam) at the dilution of 1:100 (pH 6). In cancer cells, pMST1/2 and pLATS1/2 staining intensity was considered as negative (0), weak (1+), moderate (2+) or strong (3+). The variables pMST1/2 cyt and pLATS1/2 cyt were generated consideringa distinct cytoplasmic immunoreactivity of any intensity in at least 10% of tumor cells, in the absence of nuclear staining. The variables pMST1/2 nuc and pLATS1/2 nuc were obtained consideringa distinct nuclear immunoreactivity of any intensity in at least 10% of tumor cells, independently from the presence of concomitant cytoplasmic staining.
Stromal TILs were considered as positive when representing ≥50% of the stromal surface area. 18 pMST1/2 and pLATS1/2 expression in TILs was considered positive when they were expressed in at least 10% of stromal TILs. Immunoreactions were scored independently by two investigators (CE and ADB) blinded to treatment outcomes and discordant cases were reviewed for the final assessment.
Statistical analysis
Characteristics of the study participants were summarized by descriptive statistics. 
Results
Baseline clinical-pathological characteristics of participants are summarized in Table 1 . Twenty-eight (49%) and 23 (40%) patients achieved a pCR according to the definition ypT0/is ypN0 and ypT0 ypN0, respectively.
Immunohistochemical staining of two representative cases is illustrated in Figure 1 . Expression of pMST1/2 and pLATS1/2 in TILs was recorded in 14 (25%) and 24 (42%) tumor samples, respectively (Table 2 ).
pMST1/2 was expressed in the nucleus (pMST1/2 nuc ) in 25 (44%) tumors, and 25 (44%) cases displayed an exclusive cytoplasmic localization (pMST1/2 cyt ) ( Table 2) . A lower number of tumors had exclusive pLATS1/2 cytoplasmic expression (pLATS1/2 cyt ), whereas nuclear expression of pLATS1/2 (pLATS1/2 nuc ) was recorded in 45 (78%) cases (Table 2 ).
Significant or borderline significant associations between the investigated molecular markers and standard clinical-pathological features are presented in Table 3 . pMST1/2 nuc expression was significantly more We next investigated the predictive significance of pMST1/2 and pLATS1/2 expression. We did not record any significant relationship between pLATS1/2 and pCR, irrespective of whether we considered their expression in the cytoplasm or in the nucleus (data available upon request). Likewise, neither pLATS1/2 nor pMST1/2 expression in stromal TILs predicted pCR (data available upon request). Conversely, a significant lower rate of pCR (ypT0/is ypN0) was observed for tumors expressing pMST1/2 nuc (Chi2 p = 0.005), and this association was maintained even when considering pCR as ypT0 ypN0 (Chi2 p = 0.026) (Table 4) .
Interestingly, an opposite pattern emerged when we addressed the predictive ability of pMST1/2 cyt , as the pCR rate was significantly higher in patients whose tumors carried pMST1/2 cyt (Chi2 p = 0.047 and p = 0.033 for ypT0/is ypN0 and ypT0 ypN0, respectively) ( Table 4) . Univariate analyses, presented in Figure 3 , indicated that patients with pMST1/2 nuc -expressing tumors were at increased risk of residual cancer after NAT (OR 4.91, 95%CI: 1.57-15.30 for pCR evaluated as ypT0/is ypN0; OR 3.59, 95%CI 1.14-11.34 for pCR evaluated as ypT0 ypN0), whereas those expressing pMST1/2 cyt had an opposite outcome (OR 0.34, 95%CI:
0.11-1.00 for pCR evaluated as ypT0/is ypN0; OR 0.31, 95%CI 0.10-0.93 for pCR evaluated as ypT0 ypN0).
Discussion
In the present study, we investigated the expression of activated core Hippo pathway kinases (pMST1/2 and pLATS1/2) in a series of 57 HER2-positve and triple-negative BC patients who received NAT. The message conveyed by the present study is that: i) the co-expression pattern observed between pMST1/2 nuc and nuclear pChk1 expression, and between pMST1/2 cyt and cytoplasmic TAZ expression, support the hypothesis that MST1/2 participate in different molecular networks, ii) the reduced pCR rate observed in patients with Second, our earlier data pointed to the activation of the immune-related Hippo/MST pathway as a potential protective factor in cervical cancer patients treated with NAT. 21 Thus, we also strove to investigate whether 22 Even though the nature of the immune infiltrate was not specifically assessed in the present study, a more thorough characterization of immune cells was planned in our ongoing studies, focusing on pathways potentially regulating the antitumor immunity.
We acknowledge that this study, when considering its retrospective design and the size of the cohort examined, needs to be considered as proof-of-concept. Nevertheless, the subcellular localization-dependent association between pMST1/2 and pCR, together with the different distribution of Hippo kinases, more frequently expressed in the nucleus in TNBC and in the cytoplasm in the HER2-positive setting, suggest that Hippo kinases may be endowed of subtype-specific functions. Recollecting this evidence, we envisioned that, while Hippo kinases may be intertwined with cell cycle checkpoints and DNA damage repair effectors in TNBC, they prevalently operate in the context of the canonical Hippo machinery in HER2-driven BC. This is consistent with preclinical studies describing that key Hippo pathway components are targeted by the ATM/Chk2 and ATR/Chk1 pathways, [23] [24] [25] [26] as well as with our previous findings describing a lower pCR rate in TNBC patients with elevated expression levels of DDR-linked biomarkers in their tumors. 16 Next, evidence that both estrogens, via G protein-coupled estrogen receptor (GPER), and HER2 via mechanotransduction, intersect the Hippo pathway corroborates the hypothesis of molecular subtype-dependent levels of Hippo pathway regulation in BC. 27, 28 The data herein presented provide hints which may help shape a molecular scenario where Hippo kinases exert distinct functions in relation to the underlying molecular background (subtype) of BC. However, the limitations potentially arising from the use of one single investigational approach, i.e., immunostaining, along with the hypothesis generating nature of the evidence provided, prompted the design of ad hoc studies in adequately sized cohorts to investigate the topic of interest to a deeper extent, with special emphasis being placed on TNBC given the well-established defects in the DDR machinery carried by this disease. To this end, an extensive pathway-level analysis will be carried out, envisioning the evaluation of a number of molecular processes related to the DDR and genomic stability that include, beyond central Hippo and DDR kinases, the assessment of biomarkers related to oncogene-induced replication stress and mitotic catastrophe. 29, 30 In doing so, immunohistochemical data will be integrated by the evidence from dedicated platforms for genomic and transcriptomic analyses. We will rely on samples collected in the context of a prospective, observational trial where neoadjuvant chemotherapy consists in a modified carboplatin-containing regimen, thus enabling us to gather information from patients treated with a more effective regimen than anthracycline-and taxane-containing chemotherapy. 31, 32 Overall, our data point to the Hippo kinases MST1/2 as potential predictive biomarkers in HER2-positive and triple-negative BC patients candidate to receive NAT. The complexity of molecular stimuli that tune Hippo pathway effectors and the different circuits where they operate deserves further consideration in future studies, and requires the assessment of a wider number of biomarkers for mapping specific molecular networks and functions.
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